{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:02:35Z","timestamp":1780347755970,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1741,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1038\/mt.2011.230","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T15:28:26Z","timestamp":1320161306000},"page":"221-229","source":"Crossref","is-referenced-by-count":35,"title":["Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Anniina","family":"Koski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Raki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri","family":"Nokisalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Liikanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Kangasniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Pesonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Alemany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2011.230_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/cgt.2011.7","article-title":"Clinical development directions in oncolytic viral therapy","volume":"18","author":"Eager","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2011.230_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/156800907780058817","article-title":"Clinical trials with oncolytic adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1038\/mt.2011.230_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2009.266","article-title":"Current issues and future directions of oncolytic adenoviruses","volume":"18","author":"Yamamoto","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.230_bib4","first-page":"1666","article-title":"[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1038\/mt.2011.230_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp100219n","article-title":"Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data","volume":"8","author":"Pesonen","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1038\/mt.2011.230_bib6","first-page":"1317","article-title":"Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery","volume":"63","author":"Wein","year":"2003","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2011.230_bib7","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/mt.2010.22","article-title":"Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses","volume":"18","author":"Gros","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.230_bib8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.bbabio.2010.05.005","article-title":"Mitochondria: the calcium connection","volume":"1797","author":"Contreras","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mt.2011.230_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceca.2009.05.005","article-title":"Viral calciomics: interplays between Ca2+ and virus","volume":"46","author":"Zhou","year":"2009","journal-title":"Cell Calcium"},{"key":"10.1038\/mt.2011.230_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00265-10","article-title":"Rotavirus disrupts calcium homeostasis by NSP4 viroporin activity","volume":"1","author":"Hyser","year":"2010","journal-title":"MBio"},{"key":"10.1038\/mt.2011.230_bib11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/viro.2002.1772","article-title":"Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus","volume":"305","author":"Doronin","year":"2003","journal-title":"Virology"},{"key":"10.1038\/mt.2011.230_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/138161206775474503","article-title":"L-type calcium channels","volume":"12","author":"Triggle","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1038\/mt.2011.230_bib13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2165\/00003495-199651050-00007","article-title":"Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease","volume":"51","author":"Brogden","year":"1996","journal-title":"Drugs"},{"issue":"Suppl 2","key":"10.1038\/mt.2011.230_bib14","doi-asserted-by":"crossref","first-page":"165S","DOI":"10.1111\/j.1365-2125.1986.tb02867.x","article-title":"Studies on verapamil in the treatment of essential hypertension: a review","volume":"21","author":"Midtb\u00f8","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"10.1038\/mt.2011.230_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1378\/chest.80.6.657","article-title":"Welcome\u2013the calcium channel blockers","volume":"80","author":"Karlsberg","year":"1981","journal-title":"Chest"},{"key":"10.1038\/mt.2011.230_bib16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1399-5618.2008.00636.x","article-title":"Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms","volume":"10","author":"Mallinger","year":"2008","journal-title":"Bipolar Disord"},{"key":"10.1038\/mt.2011.230_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1526-4610.2008.01298.x","article-title":"Verapamil for cluster headache. Clinical pharmacology and possible mode of action","volume":"49","author":"Tfelt-Hansen","year":"2009","journal-title":"Headache"},{"key":"10.1038\/mt.2011.230_bib18","first-page":"72","article-title":"Medications for migraine prophylaxis","volume":"73","author":"Modi","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1038\/mt.2011.230_bib19","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2011.230_bib20","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.230_bib21","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2011.230_bib22","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","author":"Pesonen","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2011.230_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2011.230_bib24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.cgt.7700539","article-title":"Intravascular adenoviral agents in cancer patients: lessons from clinical trials","volume":"9","author":"Reid","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2011.230_bib25","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus","volume":"19","author":"Cerullo","year":"2011","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"10.1038\/mt.2011.230_bib26","first-page":"S31","article-title":"Serial treatment of refractory cancer patients with GM-CSF expressing oncolytic adenovirus enhances immunological response and survival without compromising safety","volume":"19","author":"Nokisalmi","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.230_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/QCO.0b013e3283463e5b","article-title":"Calcium channel blockers and modulation of innate immunity","volume":"24","author":"Liu","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1038\/mt.2011.230_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1253\/circj.CJ-09-0467","article-title":"Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells","volume":"74","author":"Matsumori","year":"2010","journal-title":"Circ J"},{"key":"10.1038\/mt.2011.230_bib29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2249.2009.03911.x","article-title":"Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells","volume":"156","author":"Abe","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1038\/mt.2011.230_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2217\/fmb.09.28","article-title":"Oncolytic viruses from the perspective of the immune system","volume":"4","author":"Alemany","year":"2009","journal-title":"Future Microbiol"},{"key":"10.1038\/mt.2011.230_bib31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/hum.2009.135","article-title":"The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon","volume":"20","author":"Prestwich","year":"2009","journal-title":"Hum Gene Ther"},{"issue":"Pt 11","key":"10.1038\/mt.2011.230_bib32","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Alemany","year":"2000","journal-title":"J Gen Virol"},{"key":"10.1038\/mt.2011.230_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/07853890.2010.538079","article-title":"In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments","volume":"43","author":"Escutenaire","year":"2011","journal-title":"Ann Med"},{"key":"10.1038\/mt.2011.230_bib34","first-page":"6070","article-title":"Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints","volume":"62","author":"Reid","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2011.230_bib35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2011.230_bib36","first-page":"44","article-title":"Immunological features in patients with pneumonitis due to influenza A H1N1 infection","volume":"21","author":"Wen","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1038\/mt.2011.230_bib37","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2011.230_bib38","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/mt.2010.159","article-title":"Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms","volume":"18","author":"Fridlender","year":"2010","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"10.1038\/mt.2011.230_bib39","first-page":"S110","article-title":"ASGT Abstract 280. Effect of oncolytic adenovirus on tumor marker levels in cancer patients and in preclinical test systems","volume":"17","author":"Turunen","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.230_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/cgt.2008.67","article-title":"E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer","volume":"16","author":"Fukuda","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2011.230_bib41","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1128\/JVI.75.9.4176-4183.2001","article-title":"Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin","volume":"75","author":"Krasnykh","year":"2001","journal-title":"J Virol"},{"key":"10.1038\/mt.2011.230_bib42","first-page":"275","article-title":"Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells","volume":"8","author":"Kanerva","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2011.230_bib43","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1006\/mthe.2002.0599","article-title":"Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses","volume":"5","author":"Kanerva","year":"2002","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2011.230_bib44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616304683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616304683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T21:17:47Z","timestamp":1560892667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616304683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1525001616304683"],"URL":"https:\/\/doi.org\/10.1038\/mt.2011.230","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}